IL128829A - Solid phase sythesis of peptides with pre-sequences - Google Patents

Solid phase sythesis of peptides with pre-sequences

Info

Publication number
IL128829A
IL128829A IL12882997A IL12882997A IL128829A IL 128829 A IL128829 A IL 128829A IL 12882997 A IL12882997 A IL 12882997A IL 12882997 A IL12882997 A IL 12882997A IL 128829 A IL128829 A IL 128829A
Authority
IL
Israel
Prior art keywords
peptides
sythesis
sequences
solid phase
solid
Prior art date
Application number
IL12882997A
Other languages
English (en)
Other versions
IL128829A0 (en
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of IL128829A0 publication Critical patent/IL128829A0/xx
Publication of IL128829A publication Critical patent/IL128829A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Prostheses (AREA)
IL12882997A 1996-09-09 1997-09-09 Solid phase sythesis of peptides with pre-sequences IL128829A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK97196 1996-09-09
PCT/DK1997/000375 WO1998011125A1 (en) 1996-09-09 1997-09-09 Improved solid-phase peptide synthesis and agent for use in such synthesis

Publications (2)

Publication Number Publication Date
IL128829A0 IL128829A0 (en) 2000-01-31
IL128829A true IL128829A (en) 2005-08-31

Family

ID=8099561

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12882997A IL128829A (en) 1996-09-09 1997-09-09 Solid phase sythesis of peptides with pre-sequences

Country Status (14)

Country Link
US (1) US7348404B2 (de)
EP (1) EP0929567B1 (de)
JP (1) JP4405594B2 (de)
AT (1) ATE290014T1 (de)
AU (1) AU723268B2 (de)
CA (1) CA2265900C (de)
CZ (1) CZ295838B6 (de)
DE (1) DE69732640T2 (de)
DK (1) DK0929567T3 (de)
ES (1) ES2239364T3 (de)
HU (1) HU230354B1 (de)
IL (1) IL128829A (de)
PT (1) PT929567E (de)
WO (1) WO1998011125A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1950224A3 (de) * 1998-03-09 2008-12-17 Zealand Pharma A/S Pharmakologisch aktive Peptidkonjugate mit verringerter enzymatischer Hydrolysetendenz
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US7550425B2 (en) 2000-06-16 2009-06-23 Zealand Pharma A/S Diuretic peptide conjugates
EP1737889B1 (de) 2004-10-19 2010-09-08 Lonza AG Verfahren zur festphasen-peptidsynthese
CN102659938B (zh) 2005-05-04 2016-01-20 西兰制药公司 胰高血糖素样肽-2（glp-2）类似物
GB0514071D0 (en) 2005-07-07 2005-08-17 Zealand Pharma As N- or C- terminally modified small peptides
WO2007060860A1 (ja) * 2005-11-22 2007-05-31 Nihon University ピロールイミダゾールポリアミドの固相自動合成
UA96283C2 (uk) 2005-12-23 2011-10-25 Зіланд Фарма А/С Модифіковані міметики лізину
EP1991560B1 (de) * 2006-02-20 2018-04-04 Ewha University-Industry Collaboration Foundation Peptid mit zellmembranpenetrierender wirkung
CA2647867C (en) * 2006-03-29 2015-11-03 Otsuka Chemical Co., Ltd. Method for production of peptide thioester compound
AU2007319066B2 (en) 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
EP2158214B1 (de) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagonanaloga
WO2010070253A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
JP5635532B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN102292347A (zh) 2008-12-15 2011-12-21 西兰制药公司 胰高血糖素类似物
AP2011005774A0 (en) 2008-12-15 2011-06-30 Zealand Pharma As Glucagon analogues.
GEP20146056B (en) 2009-07-13 2014-03-10 Zealand Pharma As Acylated glucagon analogues
EA023925B1 (ru) 2010-04-27 2016-07-29 Зилэнд Фарма А/С Пептидные конъюгаты агонистов рецептора glp-1 и их применение
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
NZ604208A (en) 2010-06-24 2014-10-31 Zealand Pharma As Glucagon analogues
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
US9259477B2 (en) 2011-11-03 2016-02-16 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
AP2014007797A0 (en) 2011-12-23 2014-07-31 Boehringer Ingelheim Int Glucagon analogues
WO2013098408A1 (en) 2011-12-30 2013-07-04 Zealand Pharma A/S Glucagon and cck receptor agonist peptide conjugates
EP2809339A2 (de) 2012-02-03 2014-12-10 Zealand Pharma A/S Ghrelin-analoga
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
WO2014016300A1 (en) 2012-07-23 2014-01-30 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AU2014249107C1 (en) 2013-03-12 2018-07-19 Molecular Templates, Inc. CD20-binding immunotoxins for inducing cellular internalization and methods using same
US9695214B2 (en) 2013-03-15 2017-07-04 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
AU2014234400B2 (en) 2013-03-21 2017-11-16 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
ES2624961T3 (es) 2013-03-21 2017-07-18 Sanofi-Aventis Deutschland Gmbh Síntesis de productos de péptido que contienen imida cíclica
AR098065A1 (es) 2013-10-17 2016-04-27 Zealand Pharma As Análogos de glucagón acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015067716A1 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
MX2016005556A (es) 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
CA2937407A1 (en) 2014-01-27 2015-07-30 Molecular Templates, Inc. De-immunized shiga toxin a subunit effector polypeptides for applications in mammals
EP3872090A1 (de) 2014-03-11 2021-09-01 Molecular Templates, Inc. Proteine mit aminoterminalen proximalen shiga-toxin-a-untereinheiteneffektorregionen und gegen zellen gerichteten immunglobulinbindungsregionen
EP3116905B1 (de) 2014-03-11 2019-01-30 Molecular Templates, Inc. Proteine mit bindungsregionen, shiga-toxin-a-untereinheiteneffektorregionen und carboxyterminierten, endoplasmatischen retikulumlokalisierungssignalmotiven
AU2015274647C1 (en) 2014-06-11 2020-01-30 Molecular Templates, Inc. Protease-cleavage resistant, Shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
WO2015200883A2 (en) 2014-06-26 2015-12-30 Ossianix, Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
EP3218411B1 (de) 2014-11-14 2022-01-12 Ossianix, Inc. Variable neue antigen rezeptoren (vnars) gegen transferrinrezeptor (tfr) und deren verwendung
MX2017010072A (es) 2015-02-05 2017-11-09 Molecular Templates Inc Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
WO2016146739A1 (en) 2015-03-18 2016-09-22 Zealand Pharma A/S Amylin analogues
GB201506380D0 (en) 2015-04-15 2015-05-27 Serodus Asa Materials and methods for treatment of pulmonary hypertension
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
WO2016196344A1 (en) 2015-05-30 2016-12-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
AU2016297920A1 (en) 2015-07-26 2018-01-18 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes
WO2017049128A1 (en) * 2015-09-17 2017-03-23 Massachusetts Institute Of Technology Methods and systems for solid phase peptide synthesis
EP3494216A1 (de) 2016-08-06 2019-06-12 Ossianix, Inc. In-vivo-verfahren zur auswahl von peptiden, die die blut-hirn-schranke überwinden, zugehörige zusammensetzungen und verfahren zur verwendung
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
WO2018104559A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
EP3551652B1 (de) 2016-12-09 2021-01-20 Zealand Pharma A/S Duale glp-1/glp-2-agonisten
PE20191083A1 (es) 2016-12-09 2019-08-20 Zealand Pharma As Agonistas duales acilados de glp-1/glp-2
IL267990B2 (en) 2017-01-25 2024-04-01 Molecular Templates Inc Cell-targeted molecules containing Shiga toxin A subunit activators and nonimmune CD8 T-cell epitopes
WO2019089395A1 (en) 2017-11-02 2019-05-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
EP3759120A1 (de) 2018-02-27 2021-01-06 Zp Spv 3 K/S Compstatin-analoga und deren medizinische verwendungen
CA3097178A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
WO2019246288A1 (en) 2018-06-22 2019-12-26 Ossianix, Inc. Anti-cd98hc vnars for crossing the blood brain barrier and type iv vnar libraries
US20210395381A1 (en) 2018-09-14 2021-12-23 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
CA3127660A1 (en) 2019-01-23 2020-07-30 Millennium Pharmaceuticals, Inc. Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
EP3982919A1 (de) 2019-06-14 2022-04-20 Zealand Pharma A/S Pharmazeutische parenterale zusammensetzung eines dualen glp1/2-agonisten
US20220306695A1 (en) 2019-08-27 2022-09-29 Zp Spv 3 K/S Compstatin analogues and their medical uses
US11918649B2 (en) 2019-09-18 2024-03-05 Molecular Templates, Inc. PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
EP4031162A1 (de) 2019-09-20 2022-07-27 Zealand Pharma A/S Kv1.3-blocker
US20210155671A1 (en) 2019-11-24 2021-05-27 Molecular Templates, Inc. Uses of cd20-binding molecules and additional therapeutic agents
WO2021198195A1 (en) 2020-03-30 2021-10-07 Zealand Pharma A/S Agonist combination
WO2021198196A1 (en) 2020-03-30 2021-10-07 Zealand Pharma A/S Glp-1/glp-2 dual agonists
CA3185730A1 (en) 2020-07-16 2022-01-20 Anne Pernille Tofteng SHELTON Inhibitors of complement factor c3 and their medical uses
WO2022103769A1 (en) 2020-11-11 2022-05-19 Ossianix, Inc. High affinity human and monkey specific tfr-1 vnars
AU2021404497A1 (en) 2020-12-16 2023-06-08 Zealand Pharma A/S Pharmaceutical composition of glp-1/glp-2 dual agonists
MX2023006280A (es) 2020-12-16 2023-06-13 Zealand Pharma As Composicion farmaceutica de agonistas duales de glp-1/glp-2.
TW202241492A (zh) 2020-12-16 2022-11-01 丹麥商西蘭製藥公司 Ｇｌｐ－１／ｇｌｐ－２雙重促效劑之醫藥組合物
EP4294424A1 (de) 2021-02-18 2023-12-27 Zealand Pharma A/S Zusammensetzung zur behandlung von kurzdarmsyndrom
CA3213295A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
WO2022200374A1 (en) 2021-03-23 2022-09-29 Zealand Pharma A/S Kv1.3 blockers
WO2022260877A1 (en) 2021-06-07 2022-12-15 Ossianix, Inc. Shark vnars for treating covid-19
WO2022262837A1 (zh) 2021-06-18 2022-12-22 北京拓界生物医药科技有限公司 胰高血糖素类似物及其医药用途
EP4388001A1 (de) 2021-08-17 2024-06-26 Ossianix, Inc. Deimmunisierte vanar-domänen und gerüste
KR20240058121A (ko) 2021-09-03 2024-05-03 질랜드 파마 에이/에스 투여 용법
CN118354781A (zh) 2021-12-01 2024-07-16 西兰制药公司 白介素-23受体的肽抑制剂
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity
WO2024083919A1 (en) 2022-10-18 2024-04-25 Zealand Pharma A/S Inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116666A (de) * 1974-07-30 1976-02-10 Shionogi Seiyaku Kk
US5021550A (en) * 1986-10-07 1991-06-04 Thomas Jefferson University Method for preventing deletion sequences in solid phase synthesis
JP2807287B2 (ja) * 1989-10-13 1998-10-08 株式会社医学生物学研究所 ペプチドおよびその用途
CA2170030A1 (en) * 1993-09-14 1995-03-23 Robert A. Lazarus Pharmaceutical compositions containing ecotin and homologs thereof
US7176282B1 (en) * 1996-09-09 2007-02-13 Zealand Pharma A/S Solid-phase peptide synthesis and agent for use in such synthesis
EP1950224A3 (de) * 1998-03-09 2008-12-17 Zealand Pharma A/S Pharmakologisch aktive Peptidkonjugate mit verringerter enzymatischer Hydrolysetendenz

Also Published As

Publication number Publication date
JP2001500134A (ja) 2001-01-09
EP0929567B1 (de) 2005-03-02
DE69732640D1 (de) 2005-04-07
US20070004905A1 (en) 2007-01-04
HUP0102900A2 (hu) 2002-01-28
HUP0102900A3 (en) 2002-02-28
ES2239364T3 (es) 2005-09-16
CA2265900C (en) 2007-07-31
WO1998011125A1 (en) 1998-03-19
ATE290014T1 (de) 2005-03-15
AU723268B2 (en) 2000-08-24
DE69732640T2 (de) 2006-01-12
AU4199397A (en) 1998-04-02
EP0929567A1 (de) 1999-07-21
US7348404B2 (en) 2008-03-25
JP4405594B2 (ja) 2010-01-27
IL128829A0 (en) 2000-01-31
CZ80399A3 (cs) 1999-08-11
CA2265900A1 (en) 1998-03-19
CZ295838B6 (cs) 2005-11-16
HU230354B1 (hu) 2016-02-29
DK0929567T3 (da) 2005-06-27
PT929567E (pt) 2005-07-29

Similar Documents

Publication Publication Date Title
IL128829A (en) Solid phase sythesis of peptides with pre-sequences
IL142025A0 (en) Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds
IL186154A0 (en) Methods and compositions for inhibiting neoplastic cell growth
TR200001985T2 (tr) Kapa reseptörü opioid peptidleri.
IL212140A0 (en) Antibodies against acpl polypeptides
IL193886A (en) Antibodies that bind to ldcam sequences
EP0777678A4 (de)
WO1997008325A3 (en) Purified coprinus laccases and nucleic acids encoding same
IL134968A0 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2277832A1 (en) Cyclic peptides that bind to urokinase-type plasminogen activator receptor
IL113979A0 (en) Process for preparing cardiodilatin fragments highly purified cardiodilatin fragments and intermediate products for the preparation of same
ATE270303T1 (de) Gc1q-rezeptor, daran bindende hiv-1 gp120-region, verwandte peptide und antikörper
MXPA01002592A (es) Polipeptidos de transmembrana y secretados y acidos nucleicos que codifican los mismos.
Nagai Specificity of Collagenase The Action of Collagenase on Synthetic Peptides
ATE299029T1 (de) Verfahren und zusammensetzungen zur peptidsynthese (t-20)
CA2066913A1 (en) Novel binding peptides
ATE394482T1 (de) Verfahren und zusammensetzungen für peptid-, protein- und peptidomimetische synthese
WO1999005270A3 (fr) Peptides anti-microbiens de crustaces, denommes penaeidines
AU580350B2 (en) Process for synthesising peptides
EP0546087A4 (de)
HUT55800A (en) Process for producing anticoagulant peptides
Jackson et al. Identification of ε-N-trimethyllysine in a rat testis calcium-dependent regulatory protein of cyclic nucleotide phosphodiesterase
DE69619808D1 (de) Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän
AU5124993A (en) Peptide diagnostics and therapeutics for spondyloarthropathies
IL99338A0 (en) Process for the preparation of peptides by solid-phase synthesis

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees